External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

SGO 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Mar 17 / Roche and Genentech
COMPREHENSIVE GENOMIC PROFILING (CGP) IN OVARIAN CANCER HISTOTYPES: BIOMARKER PREVALENCE AND REAL-WORLD PROGNOSIS
Epithelial ovarian cancer (EOC) is a heterogeneous disease with distinct histotypes and molecular alterations signifying differing prognoses and treatment responses. CGP is increasingly used to identify potential actionable mutations (AM) for targeted therapies. AMs are underutilized for therapy assignment in EOC with non-high grade serous histotypes (non-HGSC), a subgroup characterized by resistance to chemotherapy. The goal of this study was to determine prevalence of genomic alterations (GAs) and their association with overall survival (OS) prognosis across EOC histotypes.
09:00 PM
Duration 2hrs California, USA
COMPREHENSIVE GENOMIC PROFILING (CGP) IN OVARIAN CANCER HISTOTYPES: BIOMARKER PREVALENCE AND REAL-WORLD PROGNOSIS
Venkatesh Krishnan, Zheng Kuang, Peter Lambert, Dexter Jin, Christopher Craggs, Armande Ang Houle, Ethan S. Sokol, Luciana Molinero, David Gershenson, Isabelle Ray-Coquard

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar